



JW

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------------|
| Application Number | 10593261 |
| Filing Date | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | LARSEN=5 |

U.S.PATENTS

| Examiner Initial* | Cite No | Patent Number | Kind Code ¹ | Issue Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|---------------|------------------------|------------|---|--|
| | 1 | 5552369 | | 1996-09-03 | FINDEISEN et al. | |
| | 2 | 5624949 | | 1997-04-29 | William E. HEATH Jr. et al. | |
| | 3 | 5674862 | | 1997-10-07 | William E. HEATH Jr. et al. | |
| | 4 | 5698578 | | 1997-12-16 | William E. HEATH Jr. et al. | |
| | 5 | 5710145 | | 1998-01-20 | Gaey Lowell ENGEL et al. | |
| | 6 | 5824685 | | 1998-10-20 | Peter A. CAMPOCHIARO et al. | |
| | 7 | 6015807 | | 2000-01-18 | Gaey Lowell ENGEL et al. | |
| | 8 | 6114320 | | 2000-09-05 | Lloyd P. AIELLO et al. | |

If you wish to add additional U.S. Patent citation information please click the Add button.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------------|
| Application Number | 10593261 |
| Filing Date | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | LARSEN=5 |

U.S.PATENT APPLICATION PUBLICATIONS

| Examiner Initial* | Cite No | Publication Number | Kind Code ¹ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear |
|-------------------|---------|--------------------|------------------------|------------------|---|--|
| | 1 | 20030032078 | A1 | 2003-02-13 | Gabriel H. TRAVIS | |

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

| Examiner Initial* | Cite No | Foreign Document Number ³ | Country Code ² i | Kind Code ⁴ | Publication Date | Name of Patentee or Applicant of cited Document | Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear | T ⁵ |
|-------------------|---------|--------------------------------------|-----------------------------|------------------------|------------------|---|--|--------------------------|
| | 1 | 2005107707 | WO | A1 | 2005-11-17 | Allergan, Inc. | | <input type="checkbox"/> |
| | 2 | 02080936 | WO | A1 | 2002-10-17 | Ortho McNeil Pharmaceutical, Inc. | | <input type="checkbox"/> |
| | 3 | 2005058304 | WO | A1 | 2005-06-30 | Cortical Pty Ltd. | | <input type="checkbox"/> |
| | 4 | 03104178 | WO | A1 | 2003-12-18 | Cortical Pty Ltd. | | <input type="checkbox"/> |
| | 5 | 02080935 | WO | A1 | 2002-10-17 | Ortho McNeil Pharmaceutical, Inc. | | <input type="checkbox"/> |
| | 6 | 03097052 | WO | A2 | 2003-11-27 | Celgene Corporation | | <input type="checkbox"/> |
| | 7 | 99058126 | WO | A1 | 1999-11-18 | The Endowment for Research in Human Biology, Inc. | | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------------|------------|
| Application Number | | 10593261 |
| Filing Date | | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen | |
| Art Unit | 1614 | |
| Examiner Name | | |
| Attorney Docket Number | LARSEN=5 | |

| | | | | | | | |
|----|------------|----|----|------------|--------------------------------|----------|-------------------------------------|
| 8 | 02072003 | WO | A2 | 2002-09-19 | Tomas HAGSTROM | | <input type="checkbox"/> |
| 9 | 02085400 | WO | A1 | 2002-10-31 | Supergen, Inc. | | <input type="checkbox"/> |
| 10 | 0198294 | WO | A2 | 2001-12-27 | Dupont Pharmaceuticals Company | | <input type="checkbox"/> |
| 11 | 03004058 | WO | A1 | 2003-01-16 | Santen Pharmaceutical Co. | Abstract | <input checked="" type="checkbox"/> |
| 12 | 2005056010 | WO | A1 | 2005-06-23 | Allergan, Inc. | | <input type="checkbox"/> |
| 13 | 2005011741 | WO | A2 | 2005-02-10 | Allergan, Inc. | | <input type="checkbox"/> |
| 14 | 03082081 | WO | A2 | 2003-10-09 | Maxim Pharmaceuticals, Inc. | | <input type="checkbox"/> |
| 15 | 0522226 | EP | A1 | 1993-01-13 | Ciro COSTAGLIOLA | | <input type="checkbox"/> |

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T ⁵ |
|--------------------|---------|--|--------------------------|
| | 1 | PAUL A. SIEVING et al. "Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy", Proc. Nat. Acad. Sci. (USA), February 13, 2001, Vol. 98, No. 4, pages 1835-1840 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------------|
| Application Number | 10593261 |
| Filing Date | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | LARSEN=5 |

| | | |
|----|--|--------------------------|
| 2 | ROXANA A. RADU et al., "Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargard's macular degeneration", Proc. Nat. Acad. Sci. (USA), April 15, 2003, Vol. 100, No. 8, pages 4742-4747 | <input type="checkbox"/> |
| 3 | JANET R. SPARROW, "Therapy for macular degeneration: Insights from acne", PNAS, April 15, 2003, Vol. 100, No. 8, pages 4353-4354 | <input type="checkbox"/> |
| 4 | G. B. ARDEN, "The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible", Br F Ophthalmol, 2001, Vol 85, pages 366-370 | <input type="checkbox"/> |
| 5 | LERMAN, S., "Ocular side effects of accutane therapy", Lens and Eye Toxicity Research, 1992, Vol. 9(3-4), pages 429-38. | <input type="checkbox"/> |
| 6 | DEVIPRASAD R. GOLLAPALLI et al., "Specific inactivation of isomerohydrolase activity by 11-cis-retinoids", Science Direct, Biochimica et Biophysica Acta 1651 (2003) pages 93-101 | <input type="checkbox"/> |
| 7 | DEVIPRASAD R. GOLLAPALLI et al., "All-trans-retinyl Esters Are the Substrates for Isomerization in the Vertebrate Visual Cycle", Biochemistry, April 25, 2003, Vol. 42 pages 5809-5818 | <input type="checkbox"/> |
| 8 | DEVIPRASAD R. GOLLAPALLI et al., "RPE65 Operates in the Vertebrate Visual Cycle by Stereospecifically Binding All-trans-Retinyl Esters", Biochemistry, September 17, 2003, Vol. 42, pages 11824-11830 | <input type="checkbox"/> |
| 9 | PAUL S. BERNSTEIN et al., "Mechanism of Action of Aromatic Amines That Short-Circuit the Visual Cycle", Biochemistry, 1986, Vol. 25, pages 3370-3377 | <input type="checkbox"/> |
| 10 | N DRASDO et al., "Effect of darkness on inner retinal hypoxia in diabetes" The Lancet, Vol. 359, June 29, 2002, pages 2251-2253 | <input type="checkbox"/> |
| 11 | ANETTE WINSTON et al., "Regulation of Isomerohydrolase Activity in the Visual Cycle", Biochemistry, February 3, 1998, Vol. 37, pages 2044-2050 | <input type="checkbox"/> |
| 12 | G.B. ARDEN et al., "Does dark adaptation exacerbate diabetic retinopathy? Evidence and a linking hypothesis", Vision Research, Vol. 38, 1998, pages 1723-1729 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------------|------------|
| Application Number | | 10593261 |
| Filing Date | | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen | |
| Art Unit | 1614 | |
| Examiner Name | | |
| Attorney Docket Number | LARSEN=5 | |

| | | |
|----|--|-------------------------------------|
| 13 | ANNA WROBEL et al., "Antiangiogenic activity of agonist and antagonists of retinoid nuclear receptors", Przegląd Dermatologiczny, 1999, Vol. 86, No. 4, pages 339-346 (in Polish) | <input checked="" type="checkbox"/> |
| 14 | MICHAEL F. MARMOR, et al., "Albipunctate Retinopathy with cone Dysfunction and no Abnormality in the RDH5 or RLBPI Genes", Retina 2003 United States, Vol. 23, Vol. 4, pages 543-546 | <input type="checkbox"/> |
| 15 | B. M. CALISSENDORFF, "Retinal changes degeneration or side effects caused by etretinate therapy Tigason" Klin. Mbl. Augenheilk., Vol. 194, 1989, pages 187-189 (in German) | <input checked="" type="checkbox"/> |
| 16 | TSUTOMU OIKAWA et al., "Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo", Europ J. of Pharmac., Vol. 249, 1993, pages 113-116 | <input type="checkbox"/> |
| 17 | SELIG HECHT et al., "Rod-Cone Dark Adaptation and Vitamin A", Science, New Series, Vol. 88, No. 2279, September 2, 1938, pages 219-221 | <input type="checkbox"/> |
| 18 | JOHN E. DOWLING et al., "Vitamin a Deficiency and Night Blindness", Proc. Natl. Acad. Sci. USA Vol. 44, (1958) pages 648-661 | <input type="checkbox"/> |
| 19 | RICHARD G. WELEBER et al., "Abnormal Retinal Function Associated with Isotretinoin Therapy for Acne", Arch Ophthalmol, Vol. 104, June 1986, pages 831-837 | <input type="checkbox"/> |
| 20 | H. MACLEAN et al., "Abnormal night vision with isotretinoin therapy for acne", Clinical and Experimental Dermatol, Vol. 20, page 86, January 1995, | <input type="checkbox"/> |
| 21 | ROSALIE K. CROUCH et al., "Retinoids and the Visual Process", Photochem. Photobiol., Vol. 64, pages 613-621 | <input type="checkbox"/> |
| 22 | F. T. FRAUNFELDER, et al., "Ocular Side Effects Possibly Associated with Isotretinoin Usage", Am. J. Ophthalmol, Vol. 132, 2001, pages 299-305 | <input type="checkbox"/> |
| 23 | WING C. LAW et al., "The Molecular Basis of Retinoic Acid Induced Night Blindness" Biochem. Biophys. Res. Comm., Vol. 161, No. 2, pages 825-829 | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | | |
|------------------------|---------------------|------------|
| Application Number | | 10593261 |
| Filing Date | | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen | |
| Art Unit | 1614 | |
| Examiner Name | | |
| Attorney Docket Number | LARSEN=5 | |

| | | |
|----|--|--------------------------|
| 24 | BELINDA M. WELSH et al., "Night blindness precipitated by isotretinoin in the setting of hypovitaminosis A", Australas J Dermatol, Vol. 40, 1999, pages 208-210 | <input type="checkbox"/> |
| 25 | G. P. MOSS et al., "Nomenclature of Retinoids", Arch. Biochem., Biophys. Vol. 224, No. 2, July 15, 1983, pages 728-731 | <input type="checkbox"/> |
| 26 | BRAHMA P. SANI et al., "Structural Characteristics of Synthetic Retinoids", Meth. In Enzymology, Vol. 189, 1990, pages 43-59 | <input type="checkbox"/> |
| 27 | MICHAEL KLAUS, "Structure Characteristics of Natural and Synthetic Retinoids" Meth. In Enzymology, Vol. 189, (1990) pages 3-14 | <input type="checkbox"/> |
| 28 | M. I. DAWSON et al., "Synthetic Retinoic Acid Analogs: Handling and Characterization", Meth. In Enzymology, Vol. 189, , 1990, pages 15-43 | <input type="checkbox"/> |
| 29 | GREGORY M. ACLAND et al., "Gene therapy restores vision in a canine model of childhood blindness", Nature genetics, Vol. 28, May 2001, pages 92-95 | <input type="checkbox"/> |
| 30 | T. MICHAEL REDMOND et al., "Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle", Nature Genetics, Vol. 20, December 1998, pages 344-351 | <input type="checkbox"/> |
| 31 | PAUL S. BERNSTEIN et al., "The Specific Inhibition of 11-cis-Retinyl Palmitate Formation in the Frog Eye by Diaminophenoxypentane, An inhibitor of Rhodopsin Regeneration", Vision Res., Vol. 25, No. 6, 1985, pages 741-748 | <input type="checkbox"/> |
| 32 | BROWN, et al., "Visual toxicity of synthetic retinoids", British Journal of Ophthalmology, Vol. 73, pages 286-288, 1989. | <input type="checkbox"/> |
| 33 | CAFFERY, et al., "Ocular side effects of isotretinoin therapy", Journal of the American Optometric Association, Vol. 59, No. 3, pages 221-224, March 1988. | <input type="checkbox"/> |
| 34 | DENMAN, et al., Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne", Journal of the American Academy of Dermatology, Vol. 14, No. 4, pages 692-693, April 1986. | <input type="checkbox"/> |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

| | |
|------------------------|---------------------|
| Application Number | 10593261 |
| Filing Date | 2007-07-11 |
| First Named Inventor | Lars Michael Larsen |
| Art Unit | 1614 |
| Examiner Name | |
| Attorney Docket Number | LARSEN=5 |

| | | |
|----|--|--------------------------|
| 35 | FEIST, et al., "Visual Side Effects of Isotretinoin Therapy", SOUTHERN MEDICAL JOURNAL, Vol. 80, No. 10, page 1332, October 1987. | <input type="checkbox"/> |
| 36 | FRAUNFELDER, et al., "Adverse Ocular Reactions Possibly Associated with Isotretinoin", American Journal of Ophthalmology, Vol. 100, pages 534-537, October 1985. | <input type="checkbox"/> |
| 37 | GROSS, et al., "Retinoids and the Eye", Dermatologic Clinics, Vol. 10, No. 3, pages 521-531, July 1992. | <input type="checkbox"/> |

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

| | | | |
|--------------------|---------------------------|-----------------|--|
| Examiner Signature | /Zohreh Fay/ (03/23/2012) | Date Considered | |
|--------------------|---------------------------|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.